Mark E Cooper

List of Publications by Year in Descending Order

395 papers	45,691 citations	97 h-index	207 g-index
412 ext. papers	51,128 ext. citations	8 avg, IF	7.34 L-index

#	Paper	IF	Citations
395	Adverse renal effects of NLRP3 inflammasome inhibition by MCC950 in an interventional model of diabetic kidney disease.. *Clinical Science*, **2022**, 136, 167-180	6.5	4
394	Recent advances in the pharmacotherapeutic management of diabetic kidney disease.. *Expert Opinion on Pharmacotherapy*, **2022**, 23, 791-803	4	0
393	Targeted deletion of nicotinamide adenine dinucleotide phosphate oxidase 4 from proximal tubules is dispensable for diabetic kidney disease development. *Nephrology Dialysis Transplantation* , **2021**, 36, 988-997	4.3	3
392	Processed foods drive intestinal barrier permeability and microvascular diseases. *Science Advances*, **2021**, 7,	14.3	27
391	Pro-resolving lipid mediators: regulators of inflammation, metabolism and kidney function. *Nature Reviews Nephrology*, **2021**, 17, 725-739	14.9	17
390	Potential cardiorenal benefits of efpeglenatide in diabetes. *Nature Reviews Nephrology*, **2021**, 17, 708-709	14.9	1
389	Key profibrotic and pro-inflammatory pathways in the pathogenesis of diabetic kidney disease **2021**, 1, 15-26		1
388	High Fasting Blood Glucose Level With Unknown Prior History of Diabetes Is Associated With High Risk of Severe Adverse COVID-19 Outcome.. *Frontiers in Endocrinology*, **2021**, 12, 791476	5.7	3
387	Transient Intermittent Hyperglycemia Accelerates Atherosclerosis by Promoting Myelopoiesis. *Circulation Research*, **2020**, 127, 877-892	15.7	35
386	Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease. *Frontiers in Physiology*, **2020**, 11, 518	4.6	2
385	Nox (NADPH Oxidase) 1, Nox4, and Nox5 Promote Vascular Permeability and Neovascularization in Retinopathy. *Hypertension*, **2020**, 75, 1091-1101	8.5	20
384	Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	15
383	Delineating a role for the mitochondrial permeability transition pore in diabetic kidney disease by targeting cyclophilin D. *Clinical Science*, **2020**, 134, 239-259	6.5	20
382	Complement C5a Induces Renal Injury in Diabetic Kidney Disease by Disrupting Mitochondrial Metabolic Agility. *Diabetes*, **2020**, 69, 83-98	0.9	20
381	Renal protection: What have we learnt from ADVANCE about kidney disease in type 2 diabetes?. *Diabetes, Obesity and Metabolism*, **2020**, 22 Suppl 2, 12-18	6.7	
380	Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME trial. *Nephrology Dialysis Transplantation*, **2020**, 35, 2103-2111	4.3	9
379	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1199-1208	6.7	51

378	Endothelial or vascular smooth muscle cell-specific expression of human NOX5 exacerbates renal inflammation, fibrosis and albuminuria in the Akita mouse. *Diabetologia*, **2019**, 62, 1712-1726	10.3	17
377	Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies. *Expert Opinion on Therapeutic Targets*, **2019**, 23, 579-591	6.4	82
376	Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes. *Clinical Journal of the American Society of Nephrology: CJASN*, **2019**, 14, 862-872	6.9	13
375	The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study. *Diabetologia*, **2019**, 62, 1988-1997	10.3	21
374	Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. *Journal of Clinical Investigation*, **2019**, 129, 406-421	15.9	39
373	Core Patient-Reported Outcomes (PROs) and PRO Measures (PROMs) for Polypharmacy Medicines Reviews: A Sequential Mixed-Methods Study. *Patient Preference and Adherence*, **2019**, 13, 2071-2087	2.4	1
372	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *American Journal of Kidney Diseases*, **2019**, 73, 309-315	7.4	15
371	Targeting the CDA1/CDA1BP1 Axis Retards Renal Fibrosis in Experimental Diabetic Nephropathy. *Diabetes*, **2019**, 68, 395-408	0.9	11
370	A promising outlook for diabetic kidney disease. *Nature Reviews Nephrology*, **2019**, 15, 68-70	14.9	10
369	Lipoxins Regulate the Early Growth Response-1 Network and Reverse Diabetic Kidney Disease. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 1437-1448	12.7	32
368	RAGE Deletion Confers Renoprotection by Reducing Responsiveness to Transforming Growth Factor-β and Increasing Resistance to Apoptosis. *Diabetes*, **2018**, 67, 960-973	0.9	9
367	Pathophysiological Links Between Diabetes and Blood Pressure. *Canadian Journal of Cardiology*, **2018**, 34, 585-594	3.8	24
366	Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1). *Diabetes*, **2018**, 67, 755-768	0.9	12
365	Compression force sensing regulates integrin β1 adhesive function on diabetic platelets. *Nature Communications*, **2018**, 9, 1087	17.4	24
364	New Glucose-Lowering Agents for Diabetic Kidney Disease. *Advances in Chronic Kidney Disease*, **2018**, 25, 149-157	4.7	10
363	Cardiovascular Disease and Diabetic Kidney Disease. *Seminars in Nephrology*, **2018**, 38, 217-232	4.8	36
362	Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis. *Diabetes*, **2018**, 67, 2657-2667	0.9	40
361	Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease. *Diabetologia*, **2017**, 60, 927-937	10.3	69

360	Protective Effect of Inflammasome Activation by Hydrogen Peroxide in a Mouse Model of Septic Shock. *Critical Care Medicine*, **2017**, 45, e184-e194	1.4	7
359	Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis. *Diabetes*, **2017**, 66, 2266-2277	0.9	92
358	Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. *Diabetes, Obesity and Metabolism*, **2017**, 19, 1610-1619	6.7	98
357	ESRD After Heart Failure, Myocardial Infarction, or Stroke in Type 2 Diabetic Patients With CKD. *American Journal of Kidney Diseases*, **2017**, 70, 522-531	7.4	7
356	Resveratrol Inhibits Growth of Experimental Abdominal Aortic Aneurysm Associated With Upregulation of Angiotensin-Converting Enzyme 2. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 2195-2203	9.4	48
355	NADPH Oxidase Nox5 Accelerates Renal Injury in Diabetic Nephropathy. *Diabetes*, **2017**, 66, 2691-2703	0.9	88
354	Set7 mediated interactions regulate transcriptional networks in embryonic stem cells. *Nucleic Acids Research*, **2016**, 44, 9206-9217	20.1	10
353	Mapping time-course mitochondrial adaptations in the kidney in experimental diabetes. *Clinical Science*, **2016**, 130, 711-20	6.5	68
352	Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease. *Nature Reviews Nephrology*, **2016**, 12, 73-81	14.9	277
351	Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON. *Diabetes Care*, **2016**, 39, 694-700	14.6	130
350	Deficiency in Apoptosis-Inducing Factor Recapitulates Chronic Kidney Disease via Aberrant Mitochondrial Homeostasis. *Diabetes*, **2016**, 65, 1085-98	0.9	34
349	Diabetes and Kidney Disease: Role of Oxidative Stress. *Antioxidants and Redox Signaling*, **2016**, 25, 657-684	7.4	240
348	Reactive Oxygen Species Can Provide Atheroprotection via NOX4-Dependent Inhibition of Inflammation and Vascular Remodeling. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2016**, 36, 295-307	9.4	109
347	Podocyte-specific Nox4 deletion affords renoprotection in a mouse model of diabetic nephropathy. *Diabetologia*, **2016**, 59, 379-89	10.3	86
346	Complications of Diabetes Mellitus **2016**, 1484-1581		11
345	Pathogenesis of Macrovascular Complications in Diabetes **2016**, 599-628		1
344	Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study). *Diabetes Research and Clinical Practice*, **2016**, 113, 143-51	7.4	11
343	The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis. *Diabetologia*, **2016**, 59, 1778-90	10.3	29

342	Differential effects of NOX4 and NOX1 on immune cell-mediated inflammation in the aortic sinus of diabetic ApoE-/- mice. *Clinical Science*, **2016**, 130, 1363-74	6.5	26
341	AT2R agonist, compound 21, is reno-protective against type 1 diabetic nephropathy. *Hypertension*, **2015**, 65, 1073-81	8.5	49
340	Direct Endothelial Nitric Oxide Synthase Activation Provides Atheroprotection in Diabetes-Accelerated Atherosclerosis. *Diabetes*, **2015**, 64, 3937-50	0.9	46
339	Recent advances in glucose-lowering treatment to reduce diabetic kidney disease. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 1325-33	4	4
338	Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes. *Diabetes Care*, **2015**, 38, 1891-7	14.6	48
337	Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D trial. *Diabetes and Vascular Disease Research*, **2015**, 12, 455-62	3.3	32
336	Diabetic kidney disease. *Nature Reviews Disease Primers*, **2015**, 1, 15018	51.1	241
335	miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. *Clinical Science*, **2015**, 129, 1237-49	6.5	161
334	Nox-4 and progressive kidney disease. *Current Opinion in Nephrology and Hypertension*, **2015**, 24, 74-80	3.5	31
333	Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. *American Journal of Kidney Diseases*, **2015**, 66, 441-9	7.4	75
332	50 years forward: mechanisms of hyperglycaemia-driven diabetic complications. *Diabetologia*, **2015**, 58, 1708-14	10.3	36
331	ACE2 deficiency shifts energy metabolism towards glucose utilization. *Metabolism: Clinical and Experimental*, **2015**, 64, 406-15	12.7	32
330	Identifying and interpreting novel targets that address more than one diabetic complication: a strategy for optimal end organ protection in diabetes. *Diabetology International*, **2014**, 5, 1-20	2.3	3
329	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *Lancet, The*, **2014**, 383, 1068-83	40	915
328	NADPH oxidase, NOX1, mediates vascular injury in ischemic retinopathy. *Antioxidants and Redox Signaling*, **2014**, 20, 2726-40	8.4	84
327	Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. *Diabetes*, **2014**, 63, 3091-103	0.9	87
326	Transforming growth factor-1-mediated renal fibrosis is dependent on the regulation of transforming growth factor receptor 1 expression by let-7b. *Kidney International*, **2014**, 85, 352-61	9.9	137
325	Diabetic nephropathy: renoprotective effects of pentoxifylline in the PREDIAN trial. *Nature Reviews Nephrology*, **2014**, 10, 547-8	14.9	3

324	Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy. *Diabetology and Metabolic Syndrome*, **2014**, 6, 86	5.6	24
323	Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 1237-54	12.7	246
322	New insights into the use of biomarkers of diabetic nephropathy. *Advances in Chronic Kidney Disease*, **2014**, 21, 318-26	4.7	33
321	Quinapril treatment abolishes diabetes-associated atherosclerosis in RAGE/apolipoprotein E double knockout mice. *Atherosclerosis*, **2014**, 235, 444-8	3.1	24
320	Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy. *American Journal of Nephrology*, **2014**, 40, 572-81	4.6	27
319	Nox-4 deletion reduces oxidative stress and injury by PKC-□associated mechanisms in diabetic nephropathy. *Physiological Reports*, **2014**, 2, e12192	2.6	74
318	Angiotensin-converting enzyme 2 mediates hyperfiltration associated with diabetes. *American Journal of Physiology - Renal Physiology*, **2014**, 306, F773-80	4.3	25
317	Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT. *Diabetes*, **2014**, 63, 2845-53	0.9	43
316	Role of bone-marrow- and non-bone-marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes-associated atherosclerosis. *Clinical Science*, **2014**, 127, 485-97	6.5	26
315	Dicarbonyl stress in the absence of hyperglycemia increases endothelial inflammation and atherogenesis similar to that observed in diabetes. *Diabetes*, **2014**, 63, 3915-25	0.9	64
314	Nephropathy and elevated BP in mice with podocyte-specific NADPH oxidase 5 expression. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 784-97	12.7	92
313	Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. *BMJ Open Diabetes Research and Care*, **2014**, 2, e000011	4.5	21
312	Plasma advanced glycation end products (AGEs) and NF-B activity are independent determinants of diastolic and pulse pressure. *Clinical Chemistry and Laboratory Medicine*, **2014**, 52, 129-38	5.9	12
311	Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects. *Amino Acids*, **2014**, 46, 321-6	3.5	23
310	Deficiency in mitochondrial complex I activity due to Ndufs6 gene trap insertion induces renal disease. *Antioxidants and Redox Signaling*, **2013**, 19, 331-43	8.4	31
309	Diabetic nephropathy: diagnosis and treatment. *Nature Reviews Endocrinology*, **2013**, 9, 713-23	15.2	164
308	Targeting advanced glycation endproducts and mitochondrial dysfunction in cardiovascular disease. *Current Opinion in Pharmacology*, **2013**, 13, 654-61	5.1	42
307	Mechanisms of diabetic complications. *Physiological Reviews*, **2013**, 93, 137-88	47.9	1339

306	Targeting the AGE-RAGE axis improves renal function in the context of a healthy diet low in advanced glycation end-product content. *Nephrology*, **2013**, 18, 47-56	2.2	26
305	Glucose homeostasis can be differentially modulated by varying individual components of a western diet. *Journal of Nutritional Biochemistry*, **2013**, 24, 1251-7	6.3	18
304	Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. *American Journal of Kidney Diseases*, **2013**, 61, 238-46	7.4	15
303	Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice. *Nephrology Dialysis Transplantation*, **2013**, 28, 55-62	4.3	45
302	Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. *Diabetes Care*, **2013**, 36, 3460-8	14.6	219
301	NADPH oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis. *Circulation*, **2013**, 127, 1888-902	16.7	273
300	Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. *Kidney International*, **2013**, 83, 517-23	9.9	209
299	Association of dietary sodium intake with atherogenesis in experimental diabetes and with cardiovascular disease in patients with Type 1 diabetes. *Clinical Science*, **2013**, 124, 617-26	6.5	13
298	Renoprotective effects of a novel Nox1/4 inhibitor in a mouse model of Type 2 diabetes. *Clinical Science*, **2013**, 124, 191-202	6.5	126
297	Circulating bone morphogenetic protein-7 and transforming growth factor-β1 are better predictors of renal end points in patients with type 2 diabetes mellitus. *Kidney International*, **2013**, 83, 278-84	9.9	38
296	Genetic deletion of cell division autoantigen 1 retards diabetes-associated renal injury. *Journal of the American Society of Nephrology: JASN*, **2013**, 24, 1782-92	12.7	20
295	Choosing the right angiotensin-receptor blocker for patients with diabetes: still controversial. *Cmaj*, **2013**, 185, 1023-4	3.5	1
294	Tandem inhibition of PKC in Diabetic nephropathy: it takes two to tango?. *Diabetes*, **2013**, 62, 1010-1	0.9	13
293	Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database. *American Journal of Kidney Diseases*, **2012**, 59, 75-83	7.4	139
292	Glycation in diabetic nephropathy. *Amino Acids*, **2012**, 42, 1185-92	3.5	19
291	Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. *Diabetes*, **2012**, 61, 2105-13	0.9	50
290	Activation of the Renin-Angiotensin system mediates the effects of dietary salt intake on atherogenesis in the apolipoprotein E knockout mouse. *Hypertension*, **2012**, 60, 98-105	8.5	41
289	Methylglyoxal modification of Nav1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy. *Nature Medicine*, **2012**, 18, 926-33	50.5	339

288	What are new avenues for renal protection, in addition to RAAS inhibition?. *Current Hypertension Reports*, **2012**, 14, 100-10	4.7	8
287	Oxidative stress, Nox isoforms and complications of diabetes--potential targets for novel therapies. *Journal of Cardiovascular Translational Research*, **2012**, 5, 509-18	3.3	87
286	Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. *Free Radical Biology and Medicine*, **2012**, 52, 716-723	7.8	91
285	Interaction of diabetes and ACE2 in the pathogenesis of cardiovascular disease in experimental diabetes. *Clinical Science*, **2012**, 123, 519-29	6.5	40
284	Suppression of microRNA-29 expression by TGF-1 promotes collagen expression and renal fibrosis. *Journal of the American Society of Nephrology: JASN*, **2012**, 23, 252-65	12.7	385
283	Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. *Circulation Research*, **2012**, 110, 1067-76	15.7	121
282	An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. *Kidney International*, **2011**, 80, 282-7	9.9	217
281	Targeted reduction of advanced glycation improves renal function in obesity. *Kidney International*, **2011**, 80, 190-8	9.9	83
280	Pathogenesis of diabetic nephropathy. *Journal of Diabetes Investigation*, **2011**, 2, 243-7	3.9	104
279	Targeted antioxidant therapies in hyperglycemia-mediated endothelial dysfunction. *Frontiers in Bioscience - Scholar*, **2011**, 3, 709-29	2.4	25
278	Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. *Hypertension*, **2011**, 58, 2-7	8.5	129
277	miR-200a Prevents renal fibrogenesis through repression of TGF-2 expression. *Diabetes*, **2011**, 60, 280-7	0.9	279
276	Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. *Diabetes*, **2011**, 60, 3073-80	0.9	49
275	Advanced glycation urinary protein-bound biomarkers and severity of diabetic nephropathy in man. *American Journal of Nephrology*, **2011**, 34, 347-55	4.6	30
274	Cell division autoantigen 1 enhances signaling and the profibrotic effects of transforming growth factor-n diabetic nephropathy. *Kidney International*, **2011**, 79, 199-209	9.9	21
273	Diabetes: bardoxolone improves kidney function in type 2 diabetes. *Nature Reviews Nephrology*, **2011**, 7, 552-3	14.9	12
272	Dedifferentiation of immortalized human podocytes in response to transforming growth factor-a model for diabetic podocytopathy. *Diabetes*, **2011**, 60, 1779-88	0.9	97
271	Complications of Diabetes Mellitus **2011**, 1462-1551		7

270	The Renin Angiotensin System **2011**, 323-335		
269	Role of Cell Division Autoantigen 1 (CDA1) in Cell Proliferation and Fibrosis. *Genes*, **2010**, 1, 335-48	4.2	5
268	Candesartan attenuates diabetic retinal vascular pathology by restoring glyoxalase-I function. *Diabetes*, **2010**, 59, 3208-15	0.9	83
267	E-cadherin expression is regulated by miR-192/215 by a mechanism that is independent of the profibrotic effects of transforming growth factor-beta. *Diabetes*, **2010**, 59, 1794-802	0.9	212
266	DIRECT study: a commentary. *Diabetes and Vascular Disease Research*, **2010**, 7, 319-20	3.3	2
265	Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. *Circulation Research*, **2010**, 107, 888-97	15.7	179
264	Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. *Diabetes*, **2010**, 59, 3198-207	0.9	81
263	Comparison of different measures of urinary protein excretion for prediction of renal events. *Journal of the American Society of Nephrology: JASN*, **2010**, 21, 1355-60	12.7	114
262	The pleiotropic actions of rosuvastatin confer renal benefits in the diabetic Apo-E knockout mouse. *American Journal of Physiology - Renal Physiology*, **2010**, 299, F528-35	4.3	34
261	Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2010**, 298, F763-70	4.3	88
260	Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy. *American Journal of Nephrology*, **2010**, 32, 73-82	4.6	18
259	Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms. *Nature Reviews Nephrology*, **2010**, 6, 332-41	14.9	90
258	Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. *Kidney International*, **2010**, 78, 287-95	9.9	58
257	Epigenetics: mechanisms and implications for diabetic complications. *Circulation Research*, **2010**, 107, 1403-13	15.7	157
256	Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. *Journal of Hypertension*, **2010**, 28, 780-8	1.9	64
255	The relationship between heat shock protein 72 expression in skeletal muscle and insulin sensitivity is dependent on adiposity. *Metabolism: Clinical and Experimental*, **2010**, 59, 1556-61	12.7	21
254	Lowering blood pressure reduces renal events in type 2 diabetes. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 883-92	12.7	205
253	RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 742-52	12.7	323

252	Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. *European Heart Journal*, **2009**, 30, 1128-35	9.5	147
251	c-Jun NH2-terminal kinase activity in subcutaneous adipose tissue but not nuclear factor-kappaB activity in peripheral blood mononuclear cells is an independent determinant of insulin resistance in healthy individuals. *Diabetes*, **2009**, 58, 1259-65	0.9	30
250	Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?. *Nature Reviews Endocrinology*, **2009**, 5, 138-9	15.2	1
249	Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. *Diabetes*, **2009**, 58, 1229-36	0.9	399
248	Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *Journal of the American Society of Nephrology: JASN*, **2009**, 20, 1813-21	12.7	640
247	Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. *Circulation*, **2009**, 120, 2095-104	16.7	149
246	Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic apolipoprotein E-deficient mouse. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 823-30	9.4	71
245	Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *American Journal of Kidney Diseases*, **2009**, 54, 59-69	7.4	48
244	Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. *Nature Reviews Drug Discovery*, **2009**, 8, 417-29	64.1	245
243	Metabolic memory: implications for diabetic vascular complications. *Pediatric Diabetes*, **2009**, 10, 343-6	3.6	20
242	A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *New England Journal of Medicine*, **2009**, 361, 2019-32	59.2	1695
241	Eplerenone does not attenuate diabetes-associated atherosclerosis. *Journal of Hypertension*, **2009**, 27, 1431-8	1.9	7
240	Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*, **2008**, 358, 2560-72	59.2	5250
239	Clinical review: The role of advanced glycation end products in progression and complications of diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2008**, 93, 1143-52	5.6	715
238	Localization of the ezrin binding epitope for advanced glycation endproducts. *International Journal of Biochemistry and Cell Biology*, **2008**, 40, 1570-80	5.6	6
237	Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. *Diabetes*, **2008**, 57, 2461-9	0.9	334
236	Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. *Journal of Experimental Medicine*, **2008**, 205, 2409-17	16.6	784
235	Heat shock protein expression in diabetic nephropathy. *American Journal of Physiology - Renal Physiology*, **2008**, 295, F1817-24	4.3	45

234	Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study. *Diabetes Care*, **2008**, 31, 445-7	14.6	8
233	ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 771-9	12.7	63
232	Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. *Diabetes*, **2008**, 57, 460-9	0.9	281
231	ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. *Diabetes*, **2008**, 57, 1018-25	0.9	147
230	Cardiac inflammation associated with a Western diet is mediated via activation of RAGE by AGEs. *American Journal of Physiology - Endocrinology and Metabolism*, **2008**, 295, E323-30	6	83
229	Agents in development for the treatment of diabetic nephropathy. *Expert Opinion on Emerging Drugs*, **2008**, 13, 447-63	3.7	14
228	The role of AGEs in cardiovascular disease. *Current Pharmaceutical Design*, **2008**, 14, 979-86	3.3	93
227	Diabetic patients and kidney protection: an attainable target. *Journal of Hypertension*, **2008**, 26, S3-7	1.9	5
226	Oxidative stress as a major culprit in kidney disease in diabetes. *Diabetes*, **2008**, 57, 1446-54	0.9	843
225	Therapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?. *Annals of the New York Academy of Sciences*, **2008**, 1126, 101-6	6.5	13
224	AGE, RAGE, and ROS in diabetic nephropathy. *Seminars in Nephrology*, **2007**, 27, 130-43	4.8	262
223	Can you reduce your AGE?: Strategies to prevent AGE accumulation in diabetes. *Drug Discovery Today: Therapeutic Strategies*, **2007**, 4, 85-92		2
222	Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways. *Journal of Biological Chemistry*, **2007**, 282, 11722-31	5.4	56
221	Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 1540-6	12.7	225
220	Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. *Circulation*, **2007**, 115, 2178-87	16.7	212
219	Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?. *Endocrinology*, **2007**, 148, 886-95	4.8	99
218	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. *Journal of Hypertension*, **2007**, 25, 871-6	1.9	18
217	Renal microvascular injury in diabetes: RAGE and redox signaling. *Antioxidants and Redox Signaling*, **2007**, 9, 331-42	8.4	31

216	Glycosylation Inhibitors, PKC Inhibitors and Related Interventions Against Complications **2007**, 219-228		
215	PPAR-alpha and -gamma agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. *Nephrology Dialysis Transplantation*, **2006**, 21, 2399-405	4.3	89
214	Advanced glycation end products inhibit tubulogenesis and migration of kidney epithelial cells in an ezrin-dependent manner. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 414-21	12.7	15
213	Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. *Journal of the American Society of Nephrology: JASN*, **2006**, 17, 2484-94	12.7	218
212	Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes. *Diabetes Care*, **2006**, 29, 747-8; author reply 748-9	14.6	2
211	Mechanisms of diabetic nephropathy: role of hypertension. *Hypertension*, **2006**, 48, 519-26	8.5	97
210	Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. *Clinical Journal of the American Society of Nephrology: CJASN*, **2006**, 1, 761-7	6.9	133
209	Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. *Diabetes Care*, **2006**, 29, 2210-7	14.6	47
208	Serum lipids and the progression of nephropathy in type 1 diabetes. *Diabetes Care*, **2006**, 29, 317-22	14.6	53
207	Hypertension and diabetes: role of the renin-angiotensin system. *Endocrinology and Metabolism Clinics of North America*, **2006**, 35, 469-90, vii	5.5	36
206	Renoprotective effects of renin-angiotensin-system inhibitors. *Lancet, The*, **2006**, 367, 899-900; author reply 900-2	40	28
205	The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). *Medical Journal of Australia*, **2006**, 185, 140-4	4	75
204	The assessment of kidney function by general practitioners in Australian patients with type 2 diabetes (NEFRON-2). *Medical Journal of Australia*, **2006**, 185, 259-62	4	7
203	Preventing diabetes in patients with hypertension: one more reason to block the renin-angiotensin system. *Journal of Hypertension*, **2006**, 24, S57-63	1.9	34
202	Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study. *Clinical and Experimental Nephrology*, **2006**, 10, 193-200	2.5	15
201	Vascular Endothelial Growth Factor as a Determinant of Diabetic Nephropathy **2006**, 187-199		
200	Renal Microvascular Injury in Diabetes: RAGE and Redox Signaling. *Antioxidants and Redox Signaling*, **2006**, 061221112325002	8.4	
199	Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1903-9	9.4	111

198	Agents in development for the treatment of diabetic nephropathy. *Expert Opinion on Investigational Drugs*, **2005**, 14, 279-94	5.9	12
197	Diabetes induces Na/H exchange activity and hypertrophy of rat mesenteric but not basilar arteries. *Diabetes Research and Clinical Practice*, **2005**, 70, 201-8	7.4	7
196	Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. *American Heart Journal*, **2005**, 149, 408-13	4.9	97
195	Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 2363-72	12.7	180
194	Advanced glycation end products and diabetic nephropathy. *American Journal of Therapeutics*, **2005** , 12, 562-72	1	82
193	Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. *Journal of Hypertension*, **2005**, 23, 463-73	1.9	225
192	Anti-atherosclerotic and renoprotective effects of combined angiotensin-converting enzyme and neutral endopeptidase inhibition in diabetic apolipoprotein E-knockout mice. *Journal of Hypertension*, **2005**, 23, 2071-82	1.9	19
191	Myocardial infarction increases ACE2 expression in rat and humans. *European Heart Journal*, **2005**, 26, 369-75; discussion 322-4	9.5	324
190	Myocardial infarction increases ACE2 expression in rat and humans: reply. *European Heart Journal*, **2005**, 26, 1142-1143	9.5	1
189	Temporal renal expression of angiogenic growth factors and their receptors in experimental diabetes: role of the renin-angiotensin system. *Journal of Hypertension*, **2005**, 23, 153-64	1.9	43
188	Localization of the ezrin binding epitope for glycated proteins. *Annals of the New York Academy of Sciences*, **2005**, 1043, 617-24	6.5	5
187	Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more?. *Annals of the New York Academy of Sciences*, **2005**, 1043, 644-54	6.5	28
186	Can advanced glycation end product inhibitors modulate more than one pathway to enhance renoprotection in diabetes?. *Annals of the New York Academy of Sciences*, **2005**, 1043, 750-8	6.5	5
185	Effects of advanced glycation end products on ezrin-dependent functions in LLC-PK1 proximal tubule cells. *Annals of the New York Academy of Sciences*, **2005**, 1043, 609-16	6.5	4
184	Increased tubular organic ion clearance following chronic ACE inhibition in patients with type 1 diabetes. *Kidney International*, **2005**, 67, 2494-9	9.9	19
183	Targets to retard the progression of diabetic nephropathy. *Kidney International*, **2005**, 68, 1439-45	9.9	28
182	Heparanase inhibition reduces proteinuria in a model of accelerated anti-glomerular basement membrane antibody disease. *Nephrology*, **2005**, 10, 167-73	2.2	37
181	Lipids and diabetic renal disease. *Current Diabetes Reports*, **2005**, 5, 445-8	5.6	18

180	Advanced-glycation end products in insulin-resistant states. *Current Hypertension Reports*, **2005**, 7, 96-102	4.7	23
179	Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 363-73	12.7	106
178	High glucose-induced impairment in insulin secretion is associated with reduction in islet glucokinase in a mouse model of susceptibility to islet dysfunction. *Journal of Molecular Endocrinology*, **2005**, 35, 39-48	4.5	34
177	Interactions between renin angiotensin system and advanced glycation in the kidney. *Journal of the American Society of Nephrology: JASN*, **2005**, 16, 2976-84	12.7	118
176	Anemia with impaired erythropoietin response in diabetic patients. *Archives of Internal Medicine*, **2005**, 165, 466-9		74
175	Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. *Endocrinology*, **2004**, 145, 860-6	4.8	64
174	Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats. *Clinical and Experimental Hypertension*, **2004**, 26, 69-80	2.2	9
173	Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. *Circulation*, **2004**, 109, 1536-42	16.7	180
172	Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. *Diabetes*, **2004**, 53, 2921-30	0.9	135
171	Heparanase is involved in the pathogenesis of proteinuria as a result of glomerulonephritis. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 68-78	12.7	74
170	Retinal expression of vascular endothelial growth factor is mediated by angiotensin type 1 and type 2 receptors. *Hypertension*, **2004**, 43, 276-81	8.5	71
169	Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat. *Diabetes*, **2004**, 53, 989-97	0.9	233
168	Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. *Diabetes*, **2004**, 53, 1813-23	0.9	258
167	Interactions between angiotensin II and NF-kappaB-dependent pathways in modulating macrophage infiltration in experimental diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 2139-51	12.7	130
166	Imatinib attenuates diabetes-associated atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2004**, 24, 935-42	9.4	116
165	The role of advanced glycation in reduced organic cation transport associated with experimental diabetes. *Journal of Pharmacology and Experimental Therapeutics*, **2004**, 311, 456-66	4.7	40
164	Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study. *Diabetes Care*, **2004**, 27, 874-9	14.6	61
163	Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. *Journal of the American Society of Nephrology: JASN*, **2004**, 15, 2125-38	12.7	120

162	Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. *FASEB Journal*, **2004**, 18, 176-8	0.9	210
161	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. *Kidney International*, **2004**, 65, 2309-20	9.9	685
160	Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. *Kidney International*, **2004**, 66, 1090-8	9.9	22
159	Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. *Kidney International*, **2004**, 66, 1167-72	9.9	59
158	The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. *Kidney International*, **2004**, S105-7	9.9	26
157	AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. *Kidney International*, **2004**, 66, 2137-47	9.9	174
156	Blockade of the renin-angiotensin system: better late than never. *American Journal of Kidney Diseases*, **2004**, 43, 1113-5	7.4	4
155	Use of genetic mouse models in the study of diabetic nephropathy. *Current Atherosclerosis Reports*, **2004**, 6, 197-202	6	24
154	Use of genetic mouse models in the study of diabetic nephropathy. *Current Diabetes Reports*, **2004**, 4, 435-40	5.6	46
153	Antiproteinuric effect of RAS blockade: new mechanisms. *Current Hypertension Reports*, **2004**, 6, 383-92	4.7	16
152	Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. *Circulation*, **2004**, 110, 921-7	16.7	573
151	Novel hexad repeats conserved in a putative transporter with restricted expression in cell types associated with growth, calcium exchange and homeostasis. *Experimental Cell Research*, **2004**, 293, 31-42	4.2	18
150	ACE2, a new regulator of the renin-angiotensin system. *Trends in Endocrinology and Metabolism*, **2004**, 15, 166-9	8.8	230
149	Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. *American Journal of Pathology*, **2004**, 164, 1389-97	5.8	184
148	The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. *American Journal of Hypertension*, **2004**, 17, 16S-20S; quiz A2-4	2.3	99
147	Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. *American Journal of Hypertension*, **2004**, 17, 31S-38S	2.3	126
146	New insights into the significance of microalbuminuria. *Current Opinion in Nephrology and Hypertension*, **2004**, 13, 83-91	3.5	40
145	Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy. *Current Pharmaceutical Design*, **2004**, 10, 3361-72	3.3	13

144	Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. *Hypertension*, **2003**, 41, 392-7	8.5	307
143	Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease?. *Nephrology Dialysis Transplantation*, **2003**, 18, 2293-9	4.3	16
142	The amino-terminal domains of the ezrin, radixin, and moesin (ERM) proteins bind advanced glycation end products, an interaction that may play a role in the development of diabetic complications. *Journal of Biological Chemistry*, **2003**, 278, 25783-9	5.4	50
141	Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin. *Journal of Hypertension*, **2003**, 21, 209-16	1.9	57
140	Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. *Clinical Science*, **2003**, 104, 341-347	6.5	13
139	Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system. *Clinical Science*, **2003**, 104, 341	6.5	11
138	Amylin in the periphery. *Scientific World Journal, The*, **2003**, 3, 163-75	2.2	6
137	Microalbuminuria and diabetic cardiovascular disease. *Current Atherosclerosis Reports*, **2003**, 5, 350-7	6	8
136	Ontogeny of calcitonin receptor mRNA and protein in the developing central nervous system of the rat. *Journal of Comparative Neurology*, **2003**, 456, 29-38	3.4	34
135	Reduced tubular cation transport in diabetes: prevented by ACE inhibition. *Kidney International*, **2003**, 63, 2152-61	9.9	46
134	Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes. *Kidney International*, **2003**, 64, 565-71	9.9	34
133	Calcitonin receptor isoforms expressed in the developing rat kidney. *Kidney International*, **2003**, 63, 416-26	9.9	27
132	Induction of MIF synthesis and secretion by tubular epithelial cells: a novel action of angiotensin II. *Kidney International*, **2003**, 63, 1265-75	9.9	44
131	Dialysis delayed is death prevented: a clinical perspective on the RENAAL study. *Kidney International*, **2003**, 63, 1577-9	9.9	12
130	Interactions between growth factors in the kidney: implications for progressive renal injury. *Kidney International*, **2003**, 63, 1584-5	9.9	4
129	Role of advanced glycation end products in diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, S254-8	12.7	248
128	Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease. *Archives of Biochemistry and Biophysics*, **2003**, 419, 55-62	4.1	83
127	Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. *American Journal of Pathology*, **2003**, 163, 879-87	5.8	112

126	The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. *American Journal of Pathology*, **2003**, 162, 151-60	5.8	97
125	A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. *Circulation Research*, **2003**, 92, 785-92	15.7	363
124	The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. *FASEB Journal*, **2003**, 17, 1762-4	0.9	217
123	Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. *Journal of the American Society of Nephrology: JASN*, **2003**, 14, 3061-71	12.7	75
122	Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. *Kidney International*, **2002**, 61, 31-9	9.9	68
121	Renal ischemia-reperfusion increases endothelial VEGFR-2 without increasing VEGF or VEGFR-1 expression. *Kidney International*, **2002**, 61, 1696-706	9.9	40
120	DOES COMBINED BLOCKADE OF THE RAS AND AGE FORMATION CONFER SUPERIOR RETROPROTECTION IN A HYPERTENSIVE MODEL OF DIABETIC NEPHROPATHY?. *Nephrology*, **2002**, 7, A68-A68	2.2	2
119	Combination antihypertensive therapy in the treatment of diabetic nephropathy. *Diabetes Technology and Therapeutics*, **2002**, 4, 313-21	8.1	8
118	A low-sodium diet potentiates the effects of losartan in type 2 diabetes. *Diabetes Care*, **2002**, 25, 663-71	14.6	116
117	Urinary transforming growth factor-beta excretion in patients with hypertension, type 2 diabetes, and elevated albumin excretion rate: effects of angiotensin receptor blockade and sodium restriction. *Diabetes Care*, **2002**, 25, 1072-7	14.6	75
116	Turning up the heat: heat shock proteins, hypertension and cardiovascular risk. *Journal of Hypertension*, **2002**, 20, 1713-4	1.9	2
115	Angiotensin type 2 receptor antagonism confers renal protection in a rat model of progressive renal injury. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 1773-87	12.7	106
114	Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. *Circulation*, **2002**, 106, 246-53	16.7	236
113	Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes. *Journal of Hypertension*, **2002**, 20, 707-14	1.9	25
112	Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. *Journal of Hypertension*, **2002**, 20, 985-92	1.9	69
111	Hypertension and diabetes. *Current Opinion in Nephrology and Hypertension*, **2002**, 11, 221-8	3.5	47
110	Renal expression of angiotensin receptors in long-term diabetes and the effects of angiotensin type 1 receptor blockade. *Journal of Hypertension*, **2002**, 20, 1615-24	1.9	37
109	Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. *Endocrinology*, **2002**, 143, 4907-15	4.8	127

108	Up-regulation of components of the renin-angiotensin system in the bile duct-ligated rat liver. *Gastroenterology*, **2002**, 123, 1667-76	13.3	156
107	Advanced glycation end products and diabetic complications. *Expert Opinion on Investigational Drugs*, **2002**, 11, 1205-23	5.9	94
106	Nephrin expression in the post-natal developing kidney in normotensive and hypertensive rats. *Clinical and Experimental Hypertension*, **2002**, 24, 371-81	2.2	9
105	Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes. *Medical Journal of Australia*, **2002**, 176, 296-297	4	
104	Effects of low-dose and early versus late perindopril treatment on the progression of severe diabetic nephropathy in (mREN-2)27 rats. *Journal of the American Society of Nephrology: JASN*, **2002**, 13, 684-692	12.7	14
103	Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. *Diabetes*, **2002**, 51, 3274-82	0.9	203
102	ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. *Diabetes*, **2002**, 51, 3283-9	0.9	80
101	Role of nephrin in renal disease including diabetic nephropathy. *Seminars in Nephrology*, **2002**, 22, 393-8	4.8	70
100	Angiotensin receptor blockers and the kidney: possible advantages over ACE inhibition?. *Cardiovascular Drug Reviews*, **2001**, 19, 75-86		9
99	Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. *Clinical Science*, **2001**, 100, 591	6.5	10
98	Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. *Clinical Science*, **2001**, 100, 591-599	6.5	41
97	Apoptosis and angiotensin II: yet another renal regulatory system?. *Nephron Experimental Nephrology*, **2001**, 9, 295-300		21
96	PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. *Kidney International*, **2001**, 59, 1324-32	9.9	98
95	Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. *Kidney International*, **2001**, 60, 715-21	9.9	60
94	Angiotensin-converting enzyme inhibition attenuates renal platelet-derived growth factor gene expression and cell proliferation in subtotal nephrectomy. *Nephrology*, **2001**, 6, 290-297	2.2	
93	Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. *Nephrology Dialysis Transplantation*, **2001**, 16, 1343-9	4.3	34
92	Effect of angiotensin II type 1 receptor blockade on experimental hepatic fibrogenesis. *Journal of Hepatology*, **2001**, 35, 376-85	13.4	139
91	Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *New England Journal of Medicine*, **2001**, 345, 861-9	59.2	5467

90	Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. *American Journal of Kidney Diseases*, **2001**, 37, 890-9	7.4	67
89	Internal medicine. *Medical Journal of Australia*, **2001**, 174, 9-11	4	
88	Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion. *Journal of Hypertension*, **2001**, 19, 1075-81	1.9	52
87	Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). *Journal of Clinical Investigation*, **2001**, 108, 1853-63	15.9	303
86	Aminoguanidine ameliorates overexpression of prosclerotic growth factors and collagen deposition in experimental diabetic nephropathy. *Journal of the American Society of Nephrology: JASN*, **2001**, 12, 2098-2107	12.7	88
85	ACE and diabetes **2001**, 177-184		
84	Role of angiotensin II in tubulointerstitial injury. *Seminars in Nephrology*, **2001**, 21, 554-62	4.8	50
83	Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. *Nephrology Dialysis Transplantation*, **2000**, 15, 347-54	4.3	14
82	Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. *Kidney International*, **2000**, 57, 1882-94	9.9	74
81	Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. *Kidney International*, **2000**, 58, 1469-80	9.9	64
80	Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. *Kidney International*, **2000**, 58, 2437-51	9.9	98
79	Experimental diabetic nephropathy: Is it relevant to the human disease. *Nephrology*, **2000**, 5, 177-185	2.2	4
78	Is there a role for endothelin antagonists in diabetic renal disease?. *Diabetes, Obesity and Metabolism*, **2000**, 2, 15-24	6.7	8
77	Retinal neovascularization is prevented by blockade of the renin-angiotensin system. *Hypertension*, **2000**, 36, 1099-104	8.5	201
76	The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System*, **2000**, 1, 328-35	3	103
75	Optimizing treatment of hypertension in patients with diabetes. *JAMA - Journal of the American Medical Association*, **2000**, 283, 3177-9	27.4	51
74	Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. *Hypertension* , **2000**, 36, 561-8	8.5	77
73	Endothelin receptor antagonism ameliorates mast cell infiltration, vascular hypertrophy, and epidermal growth factor expression in experimental diabetes. *Circulation Research*, **2000**, 86, 158-65	15.7	65

72	Diabetes-induced vascular hypertrophy is accompanied by activation of Na(+)-H(+) exchange and prevented by Na(+)-H(+) exchange inhibition. *Circulation Research*, **2000**, 87, 1133-40	15.7	55
71	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria **2000**, 441-459		1
70	Advanced Glycation End-Products and Diabetic Renal Disease **2000**, 247-253		
69	THE IMPORTANCE OF BLOCKADE OF THE RENIN ANGIOTENSIN AND ENDOTHELIN SYSTEMS ON PROGRESSIVE RENAL INJURY IN SUBTOTALLY NEPHRECTOMISED RATS: USE OF COMBINATION REGIMENS. *Nephrology*, **2000**, 5, A109-A109	2.2	
68	LOSS OF CIRCADIAN RHYTHM OF BLOOD PRESSURE IN THE DIABETIC SHR COMPARED TO THE CONTROL SHR. *Nephrology*, **2000**, 5, A70-A70	2.2	
67	Localization of secreted protein acidic and rich in cysteine (SPARC) expression in the rat eye. *Connective Tissue Research*, **1999**, 40, 295-303	3.3	33
66	Role of angiotensin receptor subtypes in mesenteric vascular proliferation and hypertrophy. *Hypertension*, **1999**, 34, 408-14	8.5	71
65	Diabetic nephropathy. *Diabetes Technology and Therapeutics*, **1999**, 1, 489-96	8.1	7
64	Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)27 rats. *Kidney International*, **1999**, 56, 211-21	9.9	41
63	The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury?. *Kidney International*, **1999**, 56, 1627-37	9.9	483
62	Effect of diabetes and aminoguanidine therapy on renal advanced glycation end-product binding. *Kidney International*, **1999**, 55, 907-16	9.9	54
61	Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy. *Kidney International*, **1999**, 71, S31-6	9.9	67
60	Pathological expression of renin and angiotensin II in the renal tubule after subtotal nephrectomy. Implications for the pathogenesis of tubulointerstitial fibrosis. *American Journal of Pathology*, **1999**, 155, 429-40	5.8	121
59	Cellular mechanisms of diabetic vascular hypertrophy. *Microvascular Research*, **1999**, 57, 8-18	3.7	54
58	Amylin: physiological roles in the kidney and a hypothesis for its role in hypertension. *Clinical and Experimental Pharmacology and Physiology*, **1998**, 25, 653-60	3	13
57	A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). *Kidney International*, **1998**, 54, 343-52	9.9	129
56	Renal expression of transforming growth factor-beta inducible gene-h3 (beta ig-h3) in normal and diabetic rats. *Kidney International*, **1998**, 54, 1052-62	9.9	66
55	Amylin as a growth factor during fetal and postnatal development of the rat kidney. *Kidney International*, **1998**, 53, 25-30	9.9	31

54	Pathogenesis, prevention, and treatment of diabetic nephropathy. *Lancet, The*, **1998**, 352, 213-9	40	393
53	Pathophysiology of diabetic nephropathy. *Metabolism: Clinical and Experimental*, **1998**, 47, 3-6	12.7	34
52	Attenuation of diabetes-associated mesenteric vascular hypertrophy with perindopril: morphological and molecular biological studies. *Metabolism: Clinical and Experimental*, **1998**, 47, 24-7	12.7	14
51	Drug administration in patients with diabetes mellitus. Safety considerations. *Drug Safety*, **1998**, 18, 441-55	3.1	12
50	Aminoguanidine has an anti-atherogenic effect in the cholesterol-fed rabbit. *Atherosclerosis*, **1998**, 136, 125-31	3.1	48
49	Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. *Hypertension*, **1998**, 32, 778-85	8.5	70
48	Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. *Circulation*, **1998**, 98, 2621-8	16.7	259
47	Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action. *Journal of Hypertension*, **1998**, 16, 793-9	1.9	16
46	Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy. *Journal of Hypertension*, **1998**, 16, 1603-9	1.9	23
45	Characterization of binding sites for amylin, calcitonin, and CGRP in primate kidney. *American Journal of Physiology - Renal Physiology*, **1998**, 274, F51-62	4.3	8
44	Advanced Glycation End-Products and Diabetic Renal Disease **1998**, 257-262		
43	Antihypertensive Treatment in NIDDM, With Special Reference to Abnormal Albuminuria **1998**, 419-434		2
42	Renal amylin binding in normotensive and hypertensive rats: effects of angiotensin converting enzyme inhibition with perindopril. *Journal of Hypertension*, **1997**, 15, 1245-52	1.9	4
41	Diabetic vascular complications. *Clinical and Experimental Pharmacology and Physiology*, **1997**, 24, 770-5	3	48
40	Transforming growth factor beta 1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. *Kidney International*, **1997**, 51, 1553-67	9.9	149
39	Increased density of renal amylin binding sites in experimental hypertension. *Hypertension*, **1997**, 30, 455-60	8.5	12
38	Serum total renin is increased before microalbuminuria in diabetes. *Kidney International*, **1996**, 50, 902-7	9.9	39
37	Diabetic vascular injury and ACE. Potential for pharmacological prevention of complications of later life. *Drugs and Aging*, **1996**, 8, 38-46	4.7	3

36	Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients. *Journal of Hypertension*, **1996**, 14, S11???14	1.9	11
35	Kinins or nitric oxide, or both, are involved in the antitrophic effects of angiotensin converting enzyme inhibitors on diabetes-associated mesenteric vascular hypertrophy in the rat. *Journal of Hypertension*, **1996**, 14, 601-7	1.9	25
34	Effects of liver transplantation and resection on lipid parameters: a longitudinal study. *ANZ Journal of Surgery*, **1996**, 66, 743-6	1	13
33	Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. *Kidney International*, **1996**, 50, 627-34	9.9	111
32	Extracellular matrix, growth factors and their interactions in the pathogenesis of diabetic kidney disease. *Nephrology*, **1996**, 2, 291-303	2.2	5
31	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria **1996**, 385-396		1
30	SPARC gene expression is reduced in early diabetes-related kidney growth. *Kidney International*, **1995**, 48, 1216-25	9.9	29
29	Extracellular matrix and its interactions in the diabetic kidney: a molecular biological approach. *Journal of Diabetes and Its Complications*, **1995**, 9, 252-4	3.2	12
28	Vascular changes in the diabetic kidney: effects of ACE inhibition. *Journal of Diabetes and Its Complications*, **1995**, 9, 296-300	3.2	15
27	Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition. *Journal of Diabetes and Its Complications*, **1995**, 9, 318-22	3.2	4
26	Diabetes and hypertension. Australian Diabetes Society position statement. *Medical Journal of Australia*, **1995**, 163, 372-5	4	13
25	Angiotensin-converting enzyme inhibition reduces diabetes-induced vascular hypertrophy: morphometric studies. *Journal of Vascular Research*, **1995**, 32, 183-9	1.9	21
24	Diabetes and hypertension: prognostic and therapeutic considerations. *Blood Pressure*, **1995**, 4, 329-38	1.7	7
23	Adrenomedullin and calcitonin gene-related peptide in the rat isolated kidney and in the anaesthetised rat: in vitro and in vivo effects. *European Journal of Pharmacology*, **1995**, 280, 91-4	5.3	39
22	Amylin stimulates plasma renin concentration in humans. *Hypertension*, **1995**, 26, 460-4	8.5	32
21	Microalbuminuria in diabetes. *Medical Journal of Australia*, **1994**, 161, 265-268	4	23
20	Diabetes-associated mesenteric vascular hypertrophy is attenuated by angiotensin-converting enzyme inhibition. *Diabetes*, **1994**, 43, 1221-8	0.9	67
19	Microalbuminuria in diabetes. *Medical Journal of Australia*, **1994**, 161, 574-575	4	

18	Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria **1994**, 341-351		2
17	Long-term glycemic control and the rate of progression of early diabetic kidney disease. *Kidney International*, **1993**, 44, 855-9	9.9	74
16	The management of diabetic proteinuria. Which antihypertensive agent?. *Drugs and Aging*, **1992**, 2, 301-9	4.7	9
15	Mesenteric vascular angiotensin-converting enzyme is increased in experimental diabetes mellitus. *Clinical and Experimental Pharmacology and Physiology*, **1992**, 19, 343-7	3	16
14	Diabetic renal microvascular disease: the role of hypertension and ACE inhibitors. *Clinical and Experimental Pharmacology and Physiology*, **1992**, 19, 23-7	3	6
13	Antihypertensive therapy in a model combining spontaneous hypertension with diabetes. *Kidney International*, **1992**, 41, 898-903	9.9	33
12	Angiotensin converting enzyme inhibition and calcium channel blockade in incipient diabetic nephropathy. The Melbourne Diabetic Nephropathy Study Group. *Kidney International*, **1992**, 41, 904-11	9.9	29
11	The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis. *Journal of the American Geriatrics Society*, **1990**, 38, 10-4	5.6	11
10	Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolemia. *Medical Journal of Australia*, **1990**, 152, 480-483	4	17
9	Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy. *Diabetes*, **1990**, 39, 1575-9	0.9	53
8	Intermittent diabetic microalbuminuria: association with blood pressure, glycemic control, and protein intake. *The Journal of Diabetic Complications*, **1989**, 3, 92-8		8
7	Reduced bone mass in daughters of women with osteoporosis. *New England Journal of Medicine*, **1989**, 320, 554-8	59.2	527
6	Effect of early menopause on bone mass in normal women and patients with osteoporosis. *American Journal of Medicine*, **1988**, 85, 213-6	2.4	43
5	Comparison of early renal dysfunction in type I and type II diabetes: differing associations with blood pressure and glycaemic control. *Diabetes Research and Clinical Practice*, **1988**, 4, 133-41	7.4	11
4	Glomerular filtration rate in early experimental diabetes. *The Journal of Diabetic Complications*, **1988**, 2, 8-11		9
3	Effects of genetic hypertension on diabetic nephropathy in the rat--functional and structural characteristics. *Journal of Hypertension*, **1988**, 6, 1009-16	1.9	70
2	Nuclear scanning in the diagnosis and localization of parathyroid adenomas. *Medical Journal of Australia*, **1986**, 144, 521-2, 524	4	3
1	The Pathogenesis of Macrovascular Complications Including Atherosclerosis in Diabetes635-656		1